Targeting dendritic cells with TLR-2 ligand–coated nanoparticles loaded with Mycobacterium tuberculosis epitope induce antituberculosis immunity

Das, Deepjyoti Kumar; Zafar, Mohammad Adeel; Nanda, Sidhanta; Singh, Sanpreet; Lamba, Taruna; Bashir, Hilal; Singh, Pardeep; Maurya, Sudeep Kumar; Nadeem, Sajid; Sehrawat, Sharvan; Bhalla, Vijayender; Agrewala, Javed N.

doi:10.1016/j.jbc.2022.102596

Cited by 4 publications

(2 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many commercial adjuvants contain TLR-agonists ( 168 ). Recently, a nanoparticle was targeted to DCs using Pam3CSK4 (a TLR-2 agonist) as targeting ligand ( 169 ). The use of TLR agonists as targeting ligand represents an efficient way to target DCs, but the activation of these receptors also poses the risk of modulating the immune response to potentially increase inflammation.…”

Section: Target Receptorsmentioning

confidence: 99%

Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design

Clemente,

Denis,

Silveira

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

With the deepening of our understanding of adaptive immunity at the cellular and molecular level, targeting antigens directly to immune cells has proven to be a successful strategy to develop innovative and potent vaccines. Indeed, it offers the potential to increase vaccine potency and/or modulate immune response quality while reducing off-target effects. With mRNA-vaccines establishing themselves as a versatile technology for future applications, in the last years several approaches have been explored to target nanoparticles-enabled mRNA-delivery systems to immune cells, with a focus on dendritic cells. Dendritic cells (DCs) are the most potent antigen presenting cells and key mediators of B- and T-cell immunity, and therefore considered as an ideal target for cell-specific antigen delivery. Indeed, improved potency of DC-targeted vaccines has been proved in vitro and in vivo. This review discusses the potential specific targets for immune system-directed mRNA delivery, as well as the different targeting ligand classes and delivery systems used for this purpose.

show abstract

Section: Target Receptorsmentioning

confidence: 99%

Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design

Clemente,

Denis,

Silveira

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Furthermore, the technology used to design nanoparticle-based vaccines in TB has also received attention. Das et al designed a nanoparticle formulation with TLR-2-ligand-coated nanoparticles loaded with the immunodominant peptide derived from the Acr1 protein of Mtb-targeting dendritic cells [ 88 ]. This formulation achieved a reduction in bacterial load in the lungs of infected animals.…”

Section: Challenges and Future Perspectivesmentioning

confidence: 99%

A Current Perspective on the Potential of Nanomedicine for Anti-Tuberculosis Therapy

et al. 2023

View full text Add to dashboard Cite

Tuberculosis (TB) is one of the ten infectious diseases that cause the highest amount of human mortality and morbidity. This infection, which is caused by a single pathogen, Mycobacterium tuberculosis, kills over a million people every year. There is an emerging problem of antimicrobial resistance in TB that needs urgent treatment and management. Tuberculosis treatment is complicated by its complex drug regimen, its lengthy duration and the serious side-effects caused by the drugs required. There are a number of critical issues around drug delivery and subsequent intracellular bacterial clearance. Drugs have a short lifespan in systemic circulation, which limits their activity. Nanomedicine in TB is an emerging research area which offers the potential of effective drug delivery using nanoparticles and a reduction in drug doses and side-effects to improve patient compliance with the treatment and enhance their recovery. Here, we provide a minireview of anti-TB treatment, research progress on nanomedicine and the prospects for future applications in developing innovative therapies.

show abstract

Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity

Malik,

Kaur,

Agrewala

2023

International Journal of Biological Macromolecules

View full text Add to dashboard Cite

Targeting dendritic cells with TLR-2 ligand–coated nanoparticles loaded with Mycobacterium tuberculosis epitope induce antituberculosis immunity

Cited by 4 publications

References 65 publications

Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design

Straight to the point: targeted mRNA-delivery to immune cells for improved vaccine design

A Current Perspective on the Potential of Nanomedicine for Anti-Tuberculosis Therapy

Revolutionizing medicine with toll-like receptors: A path to strengthening cellular immunity

Contact Info

Product

Resources

About